Company Description
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel.
The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products.
It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
| Country | Israel |
| Founded | 1997 |
| IPO Date | Jan 23, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 36 |
| CEO | Moshe Arkin |
Contact Details
Address: 7 Golda Meir Street, Weizmann Science Park Ness Ziona, 7403650 Israel | |
| Phone | 972 8 931 3433 |
| Website | sol-gel.com |
Stock Details
| Ticker Symbol | SLGL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001684693 |
| CUSIP Number | M8694L137 |
| ISIN Number | IL0011417206 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Moshe Arkin | Chief Executive Officer and Executive Chairman |
| Eyal Ben-Or | Chief Financial Officer |
| Dr. Itzik Yosef | Chief Operating Officer |
| Tamar Fishman Jutkowitz | Vice President and General Counsel |
| Michael Glezin | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 8, 2025 | EFFECT | Notice of Effectiveness |
| May 8, 2025 | 424B3 | Prospectus |
| May 8, 2025 | 6-K/A | Filing |
| May 5, 2025 | 6-K | Report of foreign issuer |
| Apr 30, 2025 | EFFECT | Notice of Effectiveness |
| Apr 30, 2025 | SCHEDULE 13D/A | Filing |
| Apr 29, 2025 | F-3 | Filing |
| Apr 29, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 29, 2025 | POS AM | Post-Effective amendments for registration statement |
| Apr 29, 2025 | 20-F | Annual and transition report of foreign private issuers |